摘要
目的 系统评价6种口服中成药联合阿奇霉素治疗小儿支原体肺炎的临床疗效性、安全性和经济性。方法 计算机检索EMBASE、PubMed、CochraneLibrary、中国期刊全文数据库、中文期刊全文数据库、中国生物医学文献数据库、万方数据知识服务平台口服中成药联合阿奇霉素治疗小儿支原体肺炎的随机对照试验。采用单组率、网状Meta分析6种中成药(小儿消积止咳口服液、小儿肺热咳喘口服液、小儿豉翘清热颗粒、小儿肺咳颗粒、金振口服液、小儿肺热咳喘颗粒)联合阿奇霉素治疗小儿支原体肺炎的有效性和安全性,用成本-效果分析法从支付方的角度进行经济性评价和敏感性分析。结果 纳入67篇文献,共计7166例患者。网状Meta分析结果显示,在总有效率方面,与阿奇霉素常规治疗比较,小儿消积止咳口服液、小儿豉翘清热颗粒、小儿肺咳颗粒、金振口服液与小儿肺热咳喘口服液联合阿奇霉素存在统计学差异(P<0.05),其中小儿肺咳颗粒[RR=1.20,95%CI(1.14~1.24)]与金振口服液[RR=1.20,95%CI(1.06~1.36)]联合阿奇霉素组总有效率排序第一均为0.99;在痊愈率方面,与阿奇霉素常规治疗比较,小儿消积止咳口服液[RR=1.51,95%CI(1.29~1.77)]与小儿肺热咳喘口服液[RR=1.44,95%CI(1.29~1.62)]联合阿奇霉素组存在统计学差异(P<0.05),痊愈率排序前二分别为0.64与0.61;在不良反应发生率方面,与阿奇霉素常规治疗比较,小儿肺咳颗粒[RR=0.34,95%CI(0.16~0.74)]与肺热咳喘口服液[RR=1.51,95%CI(0.28~0.73)]联合阿奇霉素存在统计学差异(P<0.05),不良反应发生率排序前二分别为0.05与0.07;小儿肺热咳喘口服液与小儿消积止咳口服液联合阿奇霉素组日治疗成本分别为47.19、65.54元,是6种口服中成药联合阿奇霉素中治愈小儿支原体肺炎的优势方案,且单因素敏感性分析证明该模型具有较好的稳健性。结论 在6种口服中成药联合阿奇霉素治�
Objective To evaluate the effectiveness, safety and economic efficiency of six Chinese patent medicines combined with Azithromycin used in children’s patients with mycoplasma pneumonia(MP). Methods The data on randomized controlled trials of Chinese patent medicine combined with Azithromycin were searched from EMBASE, PubMed, Cochrane Library, CNKI,WanFang database, CBM and VIP Database. Single group rate and network meta-analysis were used to obtain the efficacy and safety of six control Chinese patent medicines(Xiao’er Xiaoji Zhike Oral Liquid, Xiao’er Feire Kechuan Oral Liquid, Xiao’er Chiqiao Qingre granule, Xiao’er Feike granule, Jinzhen Oral Liquid, Xiao’er Feire Kechuan granule) combined with azithromycin.The cost-effectiveness analysis and sensitivity analysis were used to evaluate pharmacoeconomics from payers’ perspective. Results A total of 67 articles on RCTs were included in this study relating to 7,166 patients with MPP. The results of network meta-analysis showed that in terms of total effective rate, compared with Azithromycin conventional treatment, Xiao’er Xiaoji Zhike Oral Liquid,Xiao’er Tiaoqiao Qingle Granule, Xiao’er Feicke Granule, Jinzhen Oral Liquid and Xiao’er Feire Kechuan Oral Liquid combined with Azithromycin had statistically significant differences(P<0.05), the top of total effective rate in Xiao’er Feicke Granule [RR=1.20, 95%CI(1.14~1.24)] and Jinzhen Oral Liquid [RR=1.20, 95%CI(1.06~1.36)] combined with Azithromycin treatment group were 0.99;In terms of cure rate, compared with Azithromycin conventional treatment, Xiao’er Xiaoji Zhike Oral Liquid [RR=1.51, 95%CI(1.29 ~1.77)] and Xiao’er Feire Kechuan Oral Liquid [RR=1.44, 95%CI(1.29 ~1.62)] combined with Azithromycin showed statistical difference(P<0.05), the cure rates were 0.64 and 0.61, respectively. In terms of the incidence of adverse reactions, compared with Azithromycin conventional treatment, Xiao’er Feike Granule [RR=0.34,95%CI(0.16~0.74)] and Xiao’er Feire Kechuan Oral Liquid [RR=1.51, 95
作者
李锦田
张凯楠
周婧
颜明智
滕亮
LI Jin-Tian;ZHANG Kai-Nan;ZHOU Jing;YAN Ming-Zhi;TENG Liang(College of Public Health,Xinjiang Medical University,Urumqi 830054,China;Department of Pharmacy,The First Affiliated Hospital of Xinjiang Medical University,Urumqi 830011,China;Graduate School of Xinjiang Medical University,Urumqi 830054,China)
出处
《中国药物经济学》
2022年第8期22-31,共10页
China Journal of Pharmaceutical Economics
关键词
小儿支原体肺炎
中成药
阿奇霉素
网状Meta分析
成本-效果
Mycoplasma pneumoniae pneumonia
Azithromycin
Chinese patent medicines
Network Meta-analysis
Cost-effective
